IP Library Granted Patent US 9,745,372
Granted Patent B2
US 9,745,372 · App. 15/456,824 · Granted Aug 29, 2017

TNF binders

Inventors: Marie-Ange Buyse (Merelbeke, BE); Joachim Boucneau (De Pinte, BE); Peter Casteels (Erpe-Mere, BE); Gino Van Heeke (Eine, BE)
Assignee: Ablynx N.V.
C07K16/241C07K2317/24C07K2317/569C07K2317/94
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,745,372
App. No.
15/456,824
Granted
Aug 29, 2017
Kind
B2
Abstract

The present invention relates to amino acid sequences, compounds and polypeptides binding to tumor necrosis factor alpha (“TNF” or “TNF-alpha”). In particular, the present invention relates to improved heavy-chain immunoglobulin single variable domains (also referred to herein as “ISV's” or “ISVDs”) binding to tumor necrosis factor alpha, as well as to proteins, polypeptides and other constructs, compounds, molecules or chemical entities that comprise such ISVDs, collectively TNF binders. Other aspects, embodiments, features, uses and advantages of the invention will be clear to the skilled person based on the disclosure herein.

Claims (2)

1. An immunoglobulin single variable domain (ISVD) comprising SEQ ID NO: 40.

2. An immunoglobulin single variable domain (ISVD) consisting of SEQ ID NO: 40.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 10, 2022
From: ABLYNX N.V.
To: SANOFI
Reel/Frame 059883/0339 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 13, 2017
From: BUYSE, MARIE-ANGE; BOUCNEAU, JOACHIM; CASTEELS, PETER; VAN HEEKE, GINO
To: ABLYNX N.V.
Reel/Frame 042993/0902 →
Continuity (3)
Continuation 15501011
Provisional Application 62254375 · Nov 12, 2015
Related Publication 20170190769A1 · Jul 6, 2017